Enhanced Population-based Core Surveillance of Meningococcal Invasive Infections at Participating Centers Across Canada

Overview

Active metropolitan area surveillance for hospital admissions related to invasive infection with Neisseria meningitidis will be conducted at the 12 centers in the IMPACT network in collaboration with Public Health officials, local infection specialists and infection control practitioners during the interval from January 1, 2016 to December 31, 2022.

Full Title of Study: “IMPACT Project Protocol: Enhanced Population-based Core Surveillance of Meningococcal Invasive Infections at Participating Centers Across Canada”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Other
  • Study Primary Completion Date: December 31, 2022

Detailed Description

The objectives are 3-fold, including: 1. description of affected children and adults and the nature and outcome of the infection episodes 2. incidence rate determination in defined populations, by age, serogroup and study year 3. detailed study of the organisms recovered from cases

Interventions

  • Other: surveillance

Arms, Groups and Cohorts

  • Persons of all ages
    • Persons of all ages admitted between January 1, 2016 and December 31, 2022 with a positive result of Neisseria meningitidis isolated or detected by PCR from a normal sterile site, such as blood, CSF, joint fluid, pleural, peritoneal, pericardial fluid or tissue biopsy

Clinical Trial Outcome Measures

Primary Measures

  • Laboratory confirmed invasive meningococcal cases.
    • Time Frame: End of 2021
    • Laboratory confirmed invasive meningococcal cases.

Participating in This Clinical Trial

Inclusion Criteria

Neisseria meningitidis isolated or detected by PCR from a normally sterile body site or fluid, such as blood, CSF, joint fluid, pleural, peritoneal, pericardial fluid or tissue biopsy - Exclusion Criteria:

patients diagnosed based only on 1. clinical signs, gram stain, or antigen test 2. meningococci isolated only from respiratory tract, including conjunctiva, sinuses, middle ear/mastoid, throat, peritonsillar abscess, cervical lymph node, tracheal aspirate, bronchial lavage etc -

Gender Eligibility: All

Minimum Age: 1 Minute

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Canadian Paediatric Society
  • Collaborator
    • Pfizer
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Melanie Laffin Thibodeau, 613-526-9397, melaniel@cps.ca

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.